AnaptysBio Inc. (ANAB), a clinical-stage biotechnology company, is expected to announce 12-week results from its ongoing Phase 2b clinical trial of Rosnilimab in moderate-to-severe rheumatoid arthritis next month.
The trial has enrolled about 420 patients, who were randomized to receive three different dose levels of subcutaneously administered Rosnilimab, in addition to a placebo.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com